Journal
JOURNAL OF CONTROLLED RELEASE
Volume 263, Issue -, Pages 200-210Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2017.03.033
Keywords
Synthetic nanoparticle; Nanovaccine; T cell response; Immunotherapy
Funding
- NCI NIH HHS [R01 CA192221] Funding Source: Medline
- NIBIB NIH HHS [R01 EB013149] Funding Source: Medline
Ask authors/readers for more resources
Although vaccination is historically one of the most successful strategies for the prevention of infectious diseases, development of vaccines for cancer and many chronic infections, such as HIV, malaria, and tuberculosis, has remained a challenge. Strong and long-lasting antigen-specific Tcell responses are critical for therapy of these diseases. A major challenge in achieving a robust CD8+ T cell response is the requirement of spatio-temporal orchestration of antigen cross-presentation in antigen-presenting cells with innate stimulation. Here, we discuss the development of nanoparticle vaccine (nanovaccine) that modulates the innate immune system and enhances adaptive immunity with reduced toxicity. We address how nanovaccines can integrate multiple functions, such as lymph node targeting, antigen presentation, and stimulation of innate immunity, to achieve a robust T cell response for immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available